UK Community Advisory Board (UK-CAB)

UK-CAB 57: HIV and diabetes

Friday 22 January 2016


09.30-09.45 Arrival
09.45-10.15 Welcome and introductions, UK-CAB updates
10.00-10.30 Internal training – Garry Brough and Paul Clift
10.30-10.50  Living with HIV and diabetes: the perfect storm – George Rodgers
10.50-11.00 BREAK
11.00-11.45 Type 2 diabetes in HIV infection – Alastair Duncan, Guys and St Thomas Hospital
11.45-12.30 Insulin resistance and diabetes mellitus in HIV infection – Dr Ana Milinkovic, UCL Mortimer Market Centre
12.30-14.00 LUNCH
14.00-15.00 Fanconi trial – Dr Frank Post, Kings College Hospital
1500-15.30 HIV respiratory disease study – Dr James Brown and Dr Marc Lipman, Royal Free Hospital
15.30-15.40 BREAK
15.40-16.15 Conferences feedback
16.15-16.45 Member feedback 
16.45-17.00 AOB
17.00 Meeting close

Presentations from this meeting

Living with HIV and diabetes

Type 2 diabetes in HIV

Insulin resistance and diabetes mellitus in HIV infection

Fanconi trial

HIV respiratory disease study

Background reading

HIV and diabetes
A full guide on diabetes which is easy to read. It explains what diabetes is with a section on HIV and diabetes. You can go direct to sections of interest.

Increased blood-sugar levels and risk of type 2 diabetes
Section from the i-Base guide.

RITA – HIV and diabetes
This issue of RITA offers a detailed look at diabetes in people with HIV. It is long document, recommend reading the interview on pages 18-22 and page 46.

Side effects of HIV medicines 
Some HIV medicines may increase blood sugar levels, this articles highlights which drugs to look out for. Note that some of the drugs are no longer being used in the UK.

Complicaitions related to HIV/AIDS and Diabetes
HIV treatments may raise your risk of developing diabetes. If you have diabetes, HIV treatments may also make it harder for you to control your blood glucose levels.

Focus: Why TB-Diabetes & TB-HIV collaborative activities are important? – 14min video
Huge evidence points towards strong association between tuberculosis (TB) and diabetes, and TB and HIV! So it makes so much more sense than ever before, for TB-diabetes and TB-HIV programmes to work collaboratively together. The video focuses on screening TB patients for diabetes, which often leads to an HIV diagnosis. The first half of the video is more relevant.

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.